Jump Financial
NAUT icon

Jump Financial’s Nautilus Biotechnolgy NAUT Stock Holding History

Jump Financial’s Portfolio NAUT Stock Details NAUT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-15,000
Closed -$32K – 1872
2022
Q3 		$32K Sell
15,000
-5,000
-25% -$12.6K ﹤0.01% 1511
2022
Q2 		$54K Buy
+20,000
New +$74.4K ﹤0.01% 1497

Other funds holding NAUT

Perceptive Advisors
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CM
Cercano Management Bellevue, Washington $750M AUM 25.77% 1-Year Est. Return
MVG
Madrona Venture Group Seattle, Washington $22.1M AUM 86.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
CFM
Comprehensive Financial Management Los Gatos, California $3.05B AUM 1.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
TM
Tikvah Management Charlotte, North Carolina $329M AUM 64.12% 1-Year Est. Return
Amazon.com Inc
Amazon.com Inc Seattle, Washington $4.42B AUM 22.6% 1-Year Est. Return
AI
ArchPoint Investors Coral Gables, Florida $473M AUM 49.24% 1-Year Est. Return

Jump Financial's NAUT Position: Q4 2022 in Review

Jump Financial sold out of Nautilus Biotechnolgy (NAUT) in Q4 2022, closing a stake of 15,000 shares — an estimated $32K sold.

Jump Financial first reported a position in NAUT in Q2 2022 and held it in 2 quarters. The position peaked at $54K in Q2 2022. 81 funds tracked by Wall St. Rank hold NAUT as of Q4 2022.

  • Jump Financial reported no remaining Nautilus Biotechnolgy position as of Q4 2022 after selling out during the quarter.
  • Jump Financial sold 15,000 Nautilus Biotechnolgy shares in Q4 2022, an estimated $32K.
  • Jump Financial first reported a position in Nautilus Biotechnolgy in Q2 2022 and held it in 2 quarters.
  • Jump Financial's Nautilus Biotechnolgy position peaked at $54K in Q2 2022.
  • 81 funds tracked by Wall St. Rank held Nautilus Biotechnolgy as of Q4 2022.

Based on Jump Financial's 13F filing for Q4 2022, filed 14 Feb 2023.